What is the clinical significance of a positive CLIP‑170 (CL170) antibody test and how should it be evaluated?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Positive CLIP‑170 (CL170) Antibodies — Clinical Significance and Next Steps

Bold take: A positive CLIP‑170 antibody is a rare, non-standard autoantibody with no validated disease association or management implications; treat it as an incidental, research-level finding and do not anchor diagnosis or therapy on it. 1

What this antibody means (and doesn’t)

  • CLIP‑170 is a microtubule plus‑end–tracking protein; autoantibodies against it have been described only in small case reports without a reproducible disease link (reported in isolated SLE, limited scleroderma, glioblastoma, idiopathic pleural effusion) and are not part of any diagnostic criteria or guideline-driven panel. Morbidity/mortality/QOL are not improved by acting on this result alone. 2
  • No major rheumatology, hepatology, neurology, or thrombosis guideline includes CLIP‑170 antibodies in diagnostic algorithms. Prioritize established, outcome-relevant autoantibodies instead (ANA/ENA, anti‑dsDNA, APS aPL tests) when clinically indicated. 1, 3, 4, 5, 3

Action algorithm (driven by morbidity, mortality, QOL)

  1. Verify the result
  • Confirm assay validity with the lab:
    • Method used, titer, pattern, and controls; repeat once in a new sample if low‑titer or unexpected to exclude technical artifact. Low-titer, non-standard antibodies are common and often non-specific. 1
  1. Do NOT treat or label a disease based on CLIP‑170 alone
  • No immunosuppression or surveillance is warranted solely for CLIP‑170 positivity. 1
  1. If there are clinical red flags, investigate with guideline-backed tests only:
  • Suspicion for SLE or systemic CTD (rash/photosensitivity, oral ulcers, serositis, cytopenias, nephritis, inflammatory arthritis):
    • Order ANA by IIFA; if positive with clinical suspicion, reflex to ENA panel and anti‑dsDNA using a sensitive solid‑phase assay followed by CLIFT confirmation per guideline. Use consistent quantitative methods for follow-up if SLE diagnosed. 1, 3
  • Suspicion for antiphospholipid syndrome (thrombosis, pregnancy morbidity):
    • Test lupus anticoagulant (dRVVT/aPTT-based per ISTH), anticardiolipin IgG/IgM, anti‑β2GPI IgG/IgM; require persistence ≥12 weeks for classification. This pathway is prognostically relevant for thrombosis/pregnancy loss. 4, 5
  • Suspicion for autoimmune hepatitis (elevated AST/ALT, hyper‑IgG):
    • Use standard panel (ANA, SMA, anti‑LKM‑1, ±SLA/LP) and liver biopsy if indicated; CLIP‑170 has no role. 6
  • Suspicion for autoimmune encephalitis:
    • Follow CSF/serum neuronal antibody panel approaches; CLIP‑170 is not part of AE testing. 7, 8
  1. When to ignore CLIP‑170
  • Asymptomatic individuals or presentations with alternative explanations: document as an incidental non-validated autoantibody and proceed with standard-of-care workup only if clinically indicated. This avoids overtesting, overtreatment, and iatrogenic harm. 1

Pitfalls and how to avoid them

  • Pitfall: Anchoring on rare/non-validated antibodies.
    • Avoid: Use guideline-endorsed antibodies with proven prognostic/therapeutic impact (ANA/ENA, anti‑dsDNA strategy; aPL per ISTH). 3, 4, 5, 1
  • Pitfall: Treating serology without syndrome-level clinical correlation.
    • Avoid: Require compatible clinical features before ordering confirmatory disease-specific serologies. 1, 3
  • Pitfall: Not repeating unexpected, low-titer or discordant results.
    • Avoid: Repeat once in a new sample and confirm with the appropriate gold-standard/confirmatory method where applicable (e.g., CLIFT for dsDNA; persistence ≥12 weeks for aPL). 3, 5, 4

Bottom line for patient care

  • Do not assign a diagnosis or start therapy based on a positive CLIP‑170 antibody.
  • If symptoms suggest a defined autoimmune condition, follow the disease-specific, guideline-based serologic pathways that change outcomes; otherwise, disregard CLIP‑170 as incidental. 3, 4, 5, 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.